As demonstrated in Fig. 1, Dato-DXd was significantly more potent against TROP2-positive endometrial cancer cell lines when compared with the CTL-ADC (P = 0.0125 and P = 0.004, respectively; Fig. 1B and C). This evidence concerns the gene TACSTD2 and endometrial cancer.